GlassScriptPhysician profile
Raymond Khoudary
NPI 1396727236
$13,270.51
in general payments reported to CMS, 2019-2025
11 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $3,600 · 2021: $2,807 · 2022: $2,605 · 2023: $3,915 · 2024: $32.87 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900 · Food and Beverage: $84.92 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
| Food and Beverage | $84.92 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,805.08 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $121.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Grifols USA, LLC | $78.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.31 | 2021-2024 | Tezspire |
| Paratek Pharmaceuticals, INC. | $20.03 | 2025 | Xhance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.12 | 2024 | Takhzyro |
| Watermark Medical, INC. | $17.25 | 2021 | |
| Optinose US, INC. | $16.94 | 2025 | |
| Genzyme Corporation | $15.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Khoudary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.